Gene · 27329
Papers2,231
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 2,231
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Exploring the causal effect between lipid-modifying drugs and idiopathic pulmonary fibrosis: a drug-target Mendelian randomization study. | Lipids Health Dis | 2024 | 39090671 | PubTator, text mining | PubMed |
| Real-world experience of long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and untreated with lipoprotein apheresis. | J Clin Lipidol | 2024 | 39054196 | PubTator, text mining | PubMed |
| Circumventing Cardiovascular Calamities: The Dawn of ANGPTL3 Blockade in Severe Dyslipidemia Management. | Cardiovasc Hematol Disord Drug Targets | 2024 | 39039670 | PubTator, text mining | PubMed |
| Therapeutic Monoclonal Antibodies for Metabolic Disorders: Major Advancements and Future Perspectives. | Curr Atheroscler Rep | 2024 | 39008202 | PubTator, text mining | PubMed |
| Advances in nucleic acid-targeted therapies for cardiovascular disease prevention. | Cardiovasc Res | 2024 | 38970537 | PubTator, text mining | PubMed |
| Repurposing lipid-lowering drugs on asthma and lung function: evidence from a genetic association analysis. | J Transl Med | 2024 | 38961500 | PubTator, text mining | PubMed |
| A Randomized, Open-Label, Phase I, Single-Dose Study of Antisense Oligonucleotide, Vupanorsen, in Chinese Adults with Elevated Triglycerides. | Drugs R D | 2024 | 38949758 | PubTator, text mining | PubMed |
| Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease risk. | Eur Heart J Open | 2024 | 38895109 | PubTator, text mining | PubMed |
| Triglyceride-rich lipoprotein, remnant cholesterol, and apolipoproteins CII, CIII, and E in patients with schizophrenia. | J Lipid Res | 2024 | 38879166 | PubTator, text mining | PubMed |
| Etiology and emerging treatments for familial chylomicronemia syndrome. | Expert Rev Endocrinol Metab | 2024 | 38866702 | PubTator, text mining | PubMed |
| Decreased LDL-Cholesterol Exposure Following ANGPTL3 Inhibition Reduces Coronary Plaque Development in Homozygous Familial Hypercholesterolemia. | JACC Cardiovasc Imaging | 2024 | 38864785 | PubTator, text mining | PubMed |
| ANGPTL3 as a therapeutic target for treating homozygous familial hypercholesterolaemia: a shot in the arm for evinacumab. | Eur Heart J | 2024 | 38856677 | PubTator, text mining | PubMed |
| Associations of lipids and lipid-modifying drug target genes with atrial fibrillation risk based on genomic data. | Lipids Health Dis | 2024 | 38851763 | PubTator, text mining | PubMed |
| Evinacumab: Mechanism of action, clinical, and translational science. | Clin Transl Sci | 2024 | 38845393 | PubTator, text mining | PubMed |
| ANGPTL3 diminishes the resistance of ovarian cancer to paclitaxel by blocking the PI3K-AKT-mTOR signaling pathway. | Heliyon | 2024 | 38828336 | PubTator, text mining | PubMed |
| Identification of key markers for the stages of nonalcoholic fatty liver disease: An integrated bioinformatics analysis and experimental validation. | Dig Liver Dis | 2024 | 38824040 | PubTator, text mining | PubMed |
| Genetic association of serum lipids and lipid-modifying targets with endometriosis: Trans-ethnic Mendelian-randomization and mediation analysis. | PLoS One | 2024 | 38820493 | PubTator, text mining | PubMed |
| Lipid traits and lipid-lowering drug target genes and risk of melanoma: a mendelian randomization study. | Arch Dermatol Res | 2024 | 38819656 | PubTator, text mining | PubMed |
| Novel diamine-scaffold based N-acetylgalactosamine (GalNAc)-siRNA conjugate: synthesis and in vivo activities. | RSC Adv | 2024 | 38818366 | PubTator, text mining | PubMed |
| Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. | N Engl J Med | 2024 | 38809174 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/27329/papers?page=16